Q32 Bio financials
$9.53+3.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $53.7M | $0.00 |
| Gross profit | $53.7M | $0.00 |
| Gross margin | 100.0% | — |
| Operating income | $16.9M | -$66.1M |
| Net income | $29.8M | -$47.7M |
| Net margin | 55.5% | — |
| Diluted EPS | $2.42 | $-6.58 |
| EBITDA | $17.3M | -$65.6M |
| Operating cash flow | -$33.5M | -$67.7M |
| Free cash flow | -$33.5M | -$67.8M |
| Diluted shares | 12.3M | 9.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $48.3M | $78.0M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $9.7M | $12.7M |
| Total assets | $61.8M | $92.3M |
| Total liabilities | $19.8M | $86.7M |
| Shareholders' equity | $42.0M | $5.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology